Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4

Prostate

Volumn 71, Issue 7, 2011, Pages 755-765

  Basu, Anamika ^a   Banerjee, Hiya ^b   Rojas, Heather ^a   Martinez, Shannalee R ^a   Roy, Sourav ^b   Jia, Zhenyu ^c   Lilly, Michael B ^c   De León, Marino ^a   Casiano, Carlos A ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Health disparities; Oxidative stress; Peroxiredoxins; Prostate cancer; Tissue microarrays

Indexed keywords

MESSENGER RNA; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6; PROSTATE SPECIFIC ANTIGEN;

AGE; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION;

ADENOCARCINOMA; AGED; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEROXIREDOXINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 79953711417     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21292     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vila H, Curnen MG, Dubrow R. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev 2008;17(10):2825-2834.
3. Karami S, Young HA, Henson DE. Earlier age at diagnosis: Another dimension in cancer disparity? Cancer Detect Prev 2007;31(1):29-34.
4. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93(5):388-395. (Pubitemid 32229383)
5. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256-269. (Pubitemid 46486616)
6. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK. Oxidative stress in prostate cancer. Cancer Lett 2009;282(2):125-136.
7. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007;67(22):10823-10830. (Pubitemid 350145911)
8. So A, Hadaschik B, Sowery R, Gleave M. The role of stress proteins in prostate cancer. Curr Genomics 2007;8(4):252-261. (Pubitemid 47240702)
9. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68(6):1777-1785. (Pubitemid 351416563)
10. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by the stress oncoprotein LEDGF/ p75. Mol Cancer 2009;8:68.
11. Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009;286(2):154-160.
12. Immenschuh S, Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 2005;7(5-6):768-777. (Pubitemid 40563217)
13. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003;9(9):3418-3424. (Pubitemid 37082738)
14. Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 2009;28:93.
15. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 2006;175(4):1512-1516.
16. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, Soini Y. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002;196(3):316-323.
17. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, Hwang SC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006;11(3):269-275.
18. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, Säily M, Kinnula VL. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004;111(4):514-521. (Pubitemid 39045317)
19. Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, Yoon K, Jung M, Choe W. Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep 2009;21(6):1391-1396.
20. Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer 2010;46(9):1661-1667.
21. Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res 2009;69(5):1739-1747.
22. Lin JF, Xu J, Tian HY, Gao X, Chen QX, Gu Q, Xu GJ, Song JD, Zhao FK. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007;121(12):2596-2605. (Pubitemid 350136401)
23. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 2007;67(19):9294-9303. (Pubitemid 47535918)
24. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 2009;7(9):1543-1552.
25. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1-25.
26. Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, Sheets SM, Wu X, Casiano CA. Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005;62(1): 14-26. (Pubitemid 39614289)
27. Wittschieber D, Köllerman J, Schlomm T, Sauter G, Erbersdobler A. Nuclear grading versus gleason grading in small samples containing prostate cancer: A tissue microarray study. Pathol Oncol Res 2010;16:479-484.
28. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP. Gleason score 7 prostate cancer:A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000;56(5):730-734.
29. Shiota M, Izumi H, Miyamoto N, Onitsuka T, Kashiwagi E, Kidani A, Hirano G, Takahashi M, Ono M, Kuwano M, Naito S, Sasaguri Y, Kohno K. Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 2008;99(10):1950-1959.
30. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 2005;65(15):6773-6779. (Pubitemid 41060715)
31. Shen C, Nathan C. Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells. Mol Med 2002;8(2):95-102. (Pubitemid 35013577)
32. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 2009;28(10):1505-1517.
33. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009;69(13):1470-1479.
34. Chang TS, Cho CS, Park S, Yu S, Kang SW, Rhee SG. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem 2004;279(40):41975-41984. (Pubitemid 39313648)
35. Giguère P, Turcotte ME, Hamelin E, Parent A, Brisson J, Laroche G, Labrecque P, Dupuis G, Parent JL. Peroxiredoxin-4 interacts with and regulates the thromboxane A(2) receptor. FEBS Lett 2007;581(20):3863-3868.
36. Chowdhury SK, Raha S, Tarnopolsky MA, Singh G. Increased expression of mitochondrial glycerophosphate dehydrogenase and antioxidant enzymes in prostate cancer cell lines/cancer. Free Radic Res 2007;41(10):1116-1124. (Pubitemid 47470849)
37. De Simoni S, Goemaere J, Knoops B. Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP?. Neurosci Lett 2008;433(3):219-224.
38. Wang HQ, Du ZX, Liu BQ, Gao YY, Meng X, Guan Y, Zhang HY. TNF-related apoptosis-inducing ligand suppresses PRDX4 expression. FEBS Lett 2009;583(9):1511-1515.
39. Kalla-Singh S, Tan QW, Brito C, De León M, Garberoglio C, De León D. Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity. Growth Horm IGF Res 2010;20(2):162-170.
40. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68(3):927-936. (Pubitemid 351206772)